Nanovibronix Inc represents core values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on improving patients' lives through cutting-edge medical devices and solutions, Nanovibronix Inc sets itself apart in the healthcare industry. The company thrives on continuous research and development, delivering advanced technologies that address unmet clinical needs. Nanovibronix Inc's commitment to improving patient outcomes and its dedication to providing healthcare professionals with effective tools make it a trusted partner. With a passion for creating impactful solutions, Nanovibronix Inc consistently demonstrates its commitment to enhancing the quality of life for patients globally.

Nanovibronix Inc is primarily present in the United States and Israel.

Nanovibronix Inc has achieved significant milestones in its journey. The company has successfully developed and commercialized innovative medical devices, focused on pain management and wound healing. It has received FDA clearance and approvals for several of its groundbreaking products, including PainShield® and WoundShield™. Nanovibronix Inc has also established strategic partnerships and collaborations, further enhancing its market presence and global reach. The company's commitment to research and development has led to advancements in therapeutic ultrasound technology, improving patient outcomes and quality of life. Nanovibronix Inc continues to revolutionize the medical industry with its cutting-edge solutions and remains poised for future growth and success.

Nanovibronix Inc, a reputable company in the stock market, boasts a rich history and background. With a drive for innovation and technological advancements, Nanovibronix Inc specializes in the development of medical devices using low-intensity surface acoustic wave technology. Founded in [insert year], the company has continuously aimed to revolutionize the healthcare industry by providing non-invasive and cost-effective solutions for various medical conditions. Nanovibronix Inc has garnered recognition for its cutting-edge products, including PainShield® and WoundShield™, which have shown exceptional efficacy in pain management and wound healing. With a steadfast commitment to improving patient outcomes, Nanovibronix Inc remains at the forefront of medical device innovation.

The main competitors of Nanovibronix Inc in the market include companies such as Johnson & Johnson, Medtronic, Philips, and Siemens Healthineers.

Nanovibronix Inc primarily operates in the medical and healthcare industry.

Nanovibronix Inc operates under a business model that centers around the development and commercialization of innovative medical devices. The company specializes in utilizing proprietary low-intensity ultrasound technology for various therapeutic applications. Nanovibronix Inc's products aim to provide non-invasive and drug-free solutions for pain relief, wound healing, and infection control. By leveraging ultrasound technology, the company aims to offer cost-effective and convenient alternatives to traditional treatment methods. Nanovibronix Inc is committed to advancing healthcare through its cutting-edge devices, contributing to improved patient outcomes and overall well-being.

Pašreizējais KGV Nanovibronix nevar tikt aprēķināts.

KUV šobrīd Nanovibronix nevar aprēķināt.

AlleAktien kvalitātes vērtējums Nanovibronix ir 6/10.

Pašreiz nevar aprēķināt apgrozījumu Nanovibronix.

Pašlaik peļņa Nanovibronix nevar tikt aprēķināta.

Nanovibronix Inc is a US-based company specializing in the development and manufacturing of medical devices and retail products. The company aims to develop and distribute innovative solutions for medical problems to help patients.

Nanovibronix izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Nanovibronix vai uzņēmums nedod dividendes.

Nanovibronix ISIN ir US63008J1088.

Nanovibronix WKN ir A2QB7C.

Nanovibronix simbols ir NAOV.

Pēdējo 12 mēnešu laikā Nanovibronix maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Nanovibronix plāno maksāt dividendes 0 USD apmērā.

Nanovibronix pašreizējā dividendu rentabilitāte ir .

Nanovibronix maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Nanovibronix pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Nanovibronix tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Nanovibronix apmērā 0 USD, kas tika izmaksāta 25.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 25.07.2024..

Pēdējās dividendes izmaksa notika 25.07.2024..

Gadā 2023, Nanovibronix izmaksāja 0 USD dividendes.

Nanovibronix dividendes tiek izmaksātas USD.